Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gross

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Kidney International Reports|May 7, 2026
German Clinical Practice Guideline on Microhematuria in Children and Young Adults: Evaluating Early Detection of Kidney DiseaseKay Latta, Jan Boeckhaus, Ina Weinreich, et al.
Frontiers in Medicine|September 19, 2022
The multifaceted phenotypic and genotypic spectrum of type-IV-collagen-related nephropathy-A human genetics department experienceJasmina Ćomić, Korbinian M Riedhammer, Roman Günthner, et al.
Journal of the American Society of Nephrology : JASN|May 7, 2016
Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD-Related Systemic InflammationKirstin Andersen, Marie Sophie Kesper, Julian A Marschner, et al.
Clinical Genetics|October 11, 2020
Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trialJan Boeckhaus, Julia Hoefele, Korbinian M Riedhammer, et al.
Journal of Clinical Medicine|July 24, 2021
Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort StudyOliver Gross, Onnen Moerer, Thomas Rauen, et al.
Journal of the American Society of Nephrology : JASN|February 18, 2005
Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport diseaseVolha Ninichuk, Oliver Gross, Christoph Reichel, et al.
Kidney International|April 18, 2020
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndromeOliver Gross, Burkhard Tönshoff, Lutz T Weber, et al.
Pediatric Nephrology (Berlin, Germany)|February 4, 2025
Urinary Dickkopf-related protein 3 as a novel biomarker for kidney function decline in children with Alport syndromeJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 27, 2008
Stem cell therapy for Alport syndrome: the hope beyond the hypeOliver Gross, Dorin-Bogdan Borza, Hans-Joachim Anders, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 22, 2012
Outcomes of male patients with Alport syndrome undergoing renal replacement therapyJohanna Temme, Anneke Kramer, Kitty J Jager, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Kidney International Reports|May 7, 2026
German Clinical Practice Guideline on Microhematuria in Children and Young Adults: Evaluating Early Detection of Kidney DiseaseKay Latta, Jan Boeckhaus, Ina Weinreich, et al.
Frontiers in Medicine|September 19, 2022
The multifaceted phenotypic and genotypic spectrum of type-IV-collagen-related nephropathy-A human genetics department experienceJasmina Ćomić, Korbinian M Riedhammer, Roman Günthner, et al.
Journal of the American Society of Nephrology : JASN|May 7, 2016
Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD-Related Systemic InflammationKirstin Andersen, Marie Sophie Kesper, Julian A Marschner, et al.
Clinical Genetics|October 11, 2020
Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trialJan Boeckhaus, Julia Hoefele, Korbinian M Riedhammer, et al.
Journal of Clinical Medicine|July 24, 2021
Validation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort StudyOliver Gross, Onnen Moerer, Thomas Rauen, et al.
Journal of the American Society of Nephrology : JASN|February 18, 2005
Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport diseaseVolha Ninichuk, Oliver Gross, Christoph Reichel, et al.
Kidney International|April 18, 2020
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndromeOliver Gross, Burkhard Tönshoff, Lutz T Weber, et al.
Pediatric Nephrology (Berlin, Germany)|February 4, 2025
Urinary Dickkopf-related protein 3 as a novel biomarker for kidney function decline in children with Alport syndromeJan Boeckhaus, Burkhard Tönshoff, Lutz T Weber, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 27, 2008
Stem cell therapy for Alport syndrome: the hope beyond the hypeOliver Gross, Dorin-Bogdan Borza, Hans-Joachim Anders, et al.
Clinical Journal of the American Society of Nephrology : CJASN|September 22, 2012
Outcomes of male patients with Alport syndrome undergoing renal replacement therapyJohanna Temme, Anneke Kramer, Kitty J Jager, et al.
Pageof 15